BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 36275669)

  • 1. Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.
    Hu X; Bian C; Zhao X; Yi T
    Front Immunol; 2022; 13():1034903. PubMed ID: 36275669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
    Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
    Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor infiltrating lymphocytes in ovarian cancer.
    Santoiemma PP; Powell DJ
    Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
    Yang C; Xia BR; Zhang ZC; Zhang YJ; Lou G; Jin WL
    Front Immunol; 2020; 11():577869. PubMed ID: 33123161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Therapy Opportunities in Ovarian Cancer.
    Kandalaft LE; Odunsi K; Coukos G
    Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
    Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Ă–zdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
    McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
    J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging immunotherapies in ovarian cancer.
    Ojalvo LS; Nichols PE; Jelovac D; Emens LA
    Discov Med; 2015 Sep; 20(109):97-109. PubMed ID: 26463091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
    Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
    Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in ovarian cancer.
    Odunsi K
    Ann Oncol; 2017 Nov; 28(suppl_8):viii1-viii7. PubMed ID: 29232467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities in immunotherapy of ovarian cancer.
    Coukos G; Tanyi J; Kandalaft LE
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
    McGray AJR; Eppolito C; Miliotto A; Singel KL; Stephenson K; Lugade A; Segal BH; Keler T; Webster G; Lichty B; Kozbor D; Odunsi K
    Cancer Immunol Immunother; 2021 Dec; 70(12):3451-3460. PubMed ID: 33880648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic Cell Vaccines in Ovarian Cancer.
    Zhang X; He T; Li Y; Chen L; Liu H; Wu Y; Guo H
    Front Immunol; 2020; 11():613773. PubMed ID: 33584699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy opportunities in ovarian cancer.
    Chu CS; Kim SH; June CH; Coukos G
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of gastric cancer: Past, future perspective and challenges.
    Xie J; Fu L; Jin L
    Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
    Chodon T; Lugade AA; Battaglia S; Odunsi K
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint inhibitors in immunotherapy of ovarian cancer.
    Wang DH; Guo L; Wu XH
    Tumour Biol; 2015 Jan; 36(1):33-9. PubMed ID: 25409618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.